| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director
2 companies
Arnold L Oronsky last filed a Form 4 in October 2020, as Director, 10% Owner at PMVP. The filings on record cover 2 companies. Arnold L Oronsky's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 388,766 shares of KALV. Net of sales, the KALV filings show accumulation of 58,824 shares.
Arnold L Oronsky has 14 Form 4 filings on record from May 2015 to October 2020, across 3 companies: Director at KalVista Pharmaceuticals (KALV), 2017–2020; Director, 10% Owner at PMV Pharmaceuticals (PMVP), 2020; Director at Dynavax Technologies (DVAX), 2015–2020.
The 18 reported transactions were 12 option or other derivative awards, 4 conversions and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $2.0M and no sales.
The largest open-market purchase was 58,824 shares of KALV at an average $17.00 on September 10, 2018, about $1.0M.
Shares as reported in the last Form 4 for each company; the most recent is from October 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.